Orphazyme reveals survival plan: Possible buyers and investors have been contacted

Possible buyers and investors have been contacted as part of Orphazyme’s plan for survival. If they do not take the bait, the company will struggle to make ends meet, the plan says.

Photo: Orphazyme/PR

Embattled biotech company Orphazyme has revealed its reconstruction plans, made with legal firm Gorissen Federspiel, to save the company from the grips of bankruptcy.

It is clear that Orphazyme wants to survive – and the restructuring plan suggests it still has hopes for its key asset, arimoclomol.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs